{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T04:20:12Z","timestamp":1764044412232},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background: Nonsteroidal anti-inflammatory drug (NSAID) use has been associated with a reduced risk of colon cancer; further epidemiologic data appear consistent for stomach and esophageal adenocarcinomas. Yet, data on potential confounding effects by upper gastrointestinal tract (UGI) disorders on adenocarcinomas of the UGI are limited.<\/jats:p><jats:p>Methods: This study recruited newly diagnosed patients with esophageal adenocarcinoma (n = 220), gastric cardia adenocarcinoma (n = 277), or distal gastric adenocarcinoma (n = 441) as well as 1,356 control subjects in Los Angeles County. Unconditional multivariable logistic regression analyses were done to evaluate the association between regular NSAID use, at least two pills per week for 1 month, and these cancers.<\/jats:p><jats:p>Results: Duration of regular use of aspirin and non-aspirin NSAIDs was associated with reduced relative odds of distal gastric adenocarcinoma [&amp;gt;5 years use versus no regular use: odds ratio (OR), 0.61; 95% confidence interval, 0.40-0.92; Ptrend = 0.009] and esophageal adenocarcinoma (OR, 0.60; 95% confidence interval, 0.38-0.95; Ptrend = 0.04) in multivariable models that included history of UGI disorders and other potential confounding factors. Daily regular use was also associated with statistically significant reduced ORs of these two tumor types. No significant heterogeneity in risk estimates was noted after stratification by history of UGI disorders for any of the sites studied. However, irregular users of NSAIDs also had reduced risk of these cancers when compared with nonusers.<\/jats:p><jats:p>Conclusions: Results from this study support an inverse association between regular NSAID use and risk of esophageal and distal gastric adenocarcinomas in individuals with and without a history of UGI disorders with long duration and daily use, providing the greatest risk reduction. Reduced risk in irregular users suggests that factors other than an effect on cyclooxygenase may also be important. (Cancer Epidemiol Biomarkers Prev 2008;17(1):126\u201334)<\/jats:p>","DOI":"10.1158\/1055-9965.epi-07-0664","type":"journal-article","created":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T17:25:26Z","timestamp":1200504326000},"page":"126-134","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Adenocarcinomas in Los Angeles County"],"prefix":"10.1158","volume":"17","author":[{"given":"Lei","family":"Duan","sequence":"first","affiliation":[{"name":"1Institute for Health Promotion and Disease Prevention Research, University of Southern California and"},{"name":"2Department of Preventive Medicine, Keck School of Medicine, University of Southern California\/Norris Comprehensive Cancer Center, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna H.","family":"Wu","sequence":"additional","affiliation":[{"name":"2Department of Preventive Medicine, Keck School of Medicine, University of Southern California\/Norris Comprehensive Cancer Center, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Sullivan-Halley","sequence":"additional","affiliation":[{"name":"2Department of Preventive Medicine, Keck School of Medicine, University of Southern California\/Norris Comprehensive Cancer Center, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Bernstein","sequence":"additional","affiliation":[{"name":"2Department of Preventive Medicine, Keck School of Medicine, University of Southern California\/Norris Comprehensive Cancer Center, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2008,1,16]]},"reference":[{"key":"2022061001122726100_BIB1","doi-asserted-by":"crossref","unstructured":"Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev\u20082002;11:535\u201342.","DOI":"10.1097\/00008469-200212000-00005"},{"key":"2022061001122726100_BIB2","doi-asserted-by":"crossref","unstructured":"Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology\u20081994;5:138\u201346.","DOI":"10.1097\/00001648-199403000-00003"},{"key":"2022061001122726100_BIB3","doi-asserted-by":"crossref","unstructured":"Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer\u20082003;88:1687\u201392.","DOI":"10.1038\/sj.bjc.6600945"},{"key":"2022061001122726100_BIB4","doi-asserted-by":"crossref","unstructured":"Vainio H, Morgan G. Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers. Scand J Gastroenterol\u20081998;33:785\u20139.","DOI":"10.1080\/00365529850171404"},{"key":"2022061001122726100_BIB5","unstructured":"Vainio H, Morgan G. Non-steroidal anti-inflammatory drugs and chemoprevention of cancer. Ann Chir Gynaecol\u20082000;89:173\u20136."},{"key":"2022061001122726100_BIB6","doi-asserted-by":"crossref","unstructured":"Dai Y, Wang WH. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol\u20082006;12:2884\u20139.","DOI":"10.3748\/wjg.v12.i18.2884"},{"key":"2022061001122726100_BIB7","doi-asserted-by":"crossref","unstructured":"Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade [review]. Oncol Rep\u20082005;13:559\u201383.","DOI":"10.3892\/or.13.4.559"},{"key":"2022061001122726100_BIB8","doi-asserted-by":"crossref","unstructured":"Husain SS, Szabo IL, Tamawski AS. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol\u20082002;97:542\u201353.","DOI":"10.1111\/j.1572-0241.2002.05528.x"},{"key":"2022061001122726100_BIB9","doi-asserted-by":"crossref","unstructured":"Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res\u20082003;37:1\u201324.","DOI":"10.1159\/000071364"},{"key":"2022061001122726100_BIB10","doi-asserted-by":"crossref","unstructured":"Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med\u20082000;51:511\u201323.","DOI":"10.1146\/annurev.med.51.1.511"},{"key":"2022061001122726100_BIB11","doi-asserted-by":"crossref","unstructured":"Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer\u20081995;76:1116\u20139.","DOI":"10.1002\/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I"},{"key":"2022061001122726100_BIB12","unstructured":"Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW, Jr. Aspirin use and risk of fatal cancer. Cancer Res\u20081993;53:1322\u20137."},{"key":"2022061001122726100_BIB13","doi-asserted-by":"crossref","unstructured":"Suleiman UL, Harrison M, Britton A, McPherson K, Bates T. H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. Eur J Cancer Prev\u20082000;9:185\u201391.","DOI":"10.1097\/00008469-200006000-00006"},{"key":"2022061001122726100_BIB14","doi-asserted-by":"crossref","unstructured":"Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res\u20082006;66:4975\u201382.","DOI":"10.1158\/0008-5472.CAN-05-4253"},{"key":"2022061001122726100_BIB15","unstructured":"Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev\u20081998;7:97\u2013102."},{"key":"2022061001122726100_BIB16","doi-asserted-by":"crossref","unstructured":"Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ\u20082000;320:1642\u20136.","DOI":"10.1136\/bmj.320.7250.1642"},{"key":"2022061001122726100_BIB17","doi-asserted-by":"crossref","unstructured":"Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst\u20082003;95:1784\u201391.","DOI":"10.1093\/jnci\/djg106"},{"key":"2022061001122726100_BIB18","doi-asserted-by":"crossref","unstructured":"Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin\/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology\u20082003;124:47\u201356.","DOI":"10.1053\/gast.2003.50008"},{"key":"2022061001122726100_BIB19","doi-asserted-by":"crossref","unstructured":"Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer\u20082003;3:28.","DOI":"10.1186\/1471-2407-3-28"},{"key":"2022061001122726100_BIB20","doi-asserted-by":"crossref","unstructured":"Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer\u20082001;84:965\u20138.","DOI":"10.1054\/bjoc.2001.1702"},{"key":"2022061001122726100_BIB21","doi-asserted-by":"crossref","unstructured":"Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer\u20081999;82:473\u20136.","DOI":"10.1002\/(SICI)1097-0215(19990812)82:4<473::AID-IJC1>3.0.CO;2-K"},{"key":"2022061001122726100_BIB22","doi-asserted-by":"crossref","unstructured":"Lindblad M, Lagergren J, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev\u20082005;14:444\u201350.","DOI":"10.1158\/1055-9965.EPI-04-0467"},{"key":"2022061001122726100_BIB23","doi-asserted-by":"crossref","unstructured":"Wu AH, Crabtree JE, Bernstein L, et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer\u20082003;103:815\u201321.","DOI":"10.1002\/ijc.10887"},{"key":"2022061001122726100_BIB24","doi-asserted-by":"crossref","unstructured":"Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer\u20082003;98:940\u20138.","DOI":"10.1002\/cncr.11568"},{"key":"2022061001122726100_BIB25","doi-asserted-by":"crossref","unstructured":"Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control\u20082001;12:721\u201332.","DOI":"10.1023\/A:1011290704728"},{"key":"2022061001122726100_BIB26","doi-asserted-by":"crossref","unstructured":"Vigen C, Bernstein L, Wu AH. Occupational physical activity and risk of adenocarcinomas of the esophagus and stomach. Int J Cancer\u20082006;118:1004\u20139.","DOI":"10.1002\/ijc.21419"},{"key":"2022061001122726100_BIB27","doi-asserted-by":"crossref","unstructured":"Wu AH, Tseng CC, Hankin J, Bernstein L. Fiber intake and risk of adenocarcinomas of the esophagus and stomach. Cancer Causes Control\u20082007;18:713\u201322.","DOI":"10.1007\/s10552-007-9014-8"},{"key":"2022061001122726100_BIB28","doi-asserted-by":"crossref","unstructured":"Hamoui N, Peters JH, Schneider S, et al. Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch Surg\u20082004;139:712\u20136; discussion 6\u20137.","DOI":"10.1001\/archsurg.139.7.712"},{"key":"2022061001122726100_BIB29","doi-asserted-by":"crossref","unstructured":"Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology\u20082000;118:487\u201396.","DOI":"10.1016\/S0016-5085(00)70254-X"},{"key":"2022061001122726100_BIB30","doi-asserted-by":"crossref","unstructured":"Abdalla SI, Sanderson IR, Fitzgerald RC. Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis\u20082005;26:1627\u201333.","DOI":"10.1093\/carcin\/bgi114"},{"key":"2022061001122726100_BIB31","doi-asserted-by":"crossref","unstructured":"Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res\u20082000;60:5767\u201372.","DOI":"10.1016\/S0016-5085(00)84960-4"},{"key":"2022061001122726100_BIB32","doi-asserted-by":"crossref","unstructured":"Chen JH, Liu TY, Wu CW, Chi CW. Nonsteroidal anti-inflammatory drugs for treatment of advanced gastric cancer: cyclooxygenase-2 is involved in hepatocyte growth factor mediated tumor development and progression. Med Hypotheses\u20082001;57:503\u20135.","DOI":"10.1054\/mehy.2001.1374"},{"key":"2022061001122726100_BIB33","doi-asserted-by":"crossref","unstructured":"Buttar NS, Wang KK, Anderson MA, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst\u20082002;94:422\u20139.","DOI":"10.1093\/jnci\/94.6.422"},{"key":"2022061001122726100_BIB34","doi-asserted-by":"crossref","unstructured":"Kandil HM, Tanner G, Smalley W, Halter S, Radhika A, Dubois RN. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci\u20082001;46:785\u20139.","DOI":"10.1023\/A:1010700400960"},{"key":"2022061001122726100_BIB35","doi-asserted-by":"crossref","unstructured":"Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H, Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol\u20081998;27 Suppl 1:S47\u201352.","DOI":"10.1097\/00004836-199800001-00009"},{"key":"2022061001122726100_BIB36","doi-asserted-by":"crossref","unstructured":"Tsuji S, Kawano S, Sawaoka H, et al. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids\u20081996;55:179\u201383.","DOI":"10.1016\/S0952-3278(96)90095-2"},{"key":"2022061001122726100_BIB37","unstructured":"Coogan PF, Rosenberg L, Palmer JR, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev\u20082000;9:119\u201323."},{"key":"2022061001122726100_BIB38","doi-asserted-by":"crossref","unstructured":"Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol\u20082005;6:945\u201352.","DOI":"10.1016\/S1470-2045(05)70431-9"},{"key":"2022061001122726100_BIB39","doi-asserted-by":"crossref","unstructured":"Sugawa C, Takekuma Y, Lucas CE, Amamoto H. Bleeding esophageal ulcers caused by NSAIDs. Surg Endosc\u20081997;11:143\u20136.","DOI":"10.1007\/s004649900317"},{"key":"2022061001122726100_BIB40","doi-asserted-by":"crossref","unstructured":"Tarnawski AS, Caves TC. Aspirin in the XXI century: its major clinical impact, novel mechanisms of action, and new safer formulations. Gastroenterology\u20082004;127:341\u20133.","DOI":"10.1053\/j.gastro.2004.05.037"},{"key":"2022061001122726100_BIB41","doi-asserted-by":"crossref","unstructured":"Gammon MD, Terry MB, Arber N, et al. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev\u20082004;13:34\u20139.","DOI":"10.1158\/1055-9965.EPI-03-0198"},{"key":"2022061001122726100_BIB42","doi-asserted-by":"crossref","unstructured":"Tsibouris P, Hendrickse MT, Isaacs PE. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther\u20082004;20:645\u201355.","DOI":"10.1111\/j.1365-2036.2004.02150.x"}],"container-title":["Cancer Epidemiology, Biomarkers &amp; Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/17\/1\/126\/2266099\/126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/17\/1\/126\/2266099\/126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T10:06:30Z","timestamp":1708509990000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cebp\/article\/17\/1\/126\/177255\/Nonsteroidal-Anti-inflammatory-Drugs-and-Risk-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,1,16]]},"published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1055-9965.epi-07-0664","relation":{},"ISSN":["1055-9965","1538-7755"],"issn-type":[{"value":"1055-9965","type":"print"},{"value":"1538-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}